DE69435212D1 - Behandlung von Diabetes - Google Patents

Behandlung von Diabetes

Info

Publication number
DE69435212D1
DE69435212D1 DE69435212T DE69435212T DE69435212D1 DE 69435212 D1 DE69435212 D1 DE 69435212D1 DE 69435212 T DE69435212 T DE 69435212T DE 69435212 T DE69435212 T DE 69435212T DE 69435212 D1 DE69435212 D1 DE 69435212D1
Authority
DE
Germany
Prior art keywords
treatment
diabetes
cells
gene
prepograstrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69435212T
Other languages
English (en)
Inventor
Ronald V Nardi
Stephan J Brand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Waratah Pharmaceuticals Inc
General Hospital Corp
Original Assignee
Waratah Pharmaceuticals Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc, General Hospital Corp filed Critical Waratah Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69435212D1 publication Critical patent/DE69435212D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69435212T 1994-01-24 1994-01-24 Behandlung von Diabetes Expired - Fee Related DE69435212D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04076250A EP1466618B1 (de) 1994-01-24 1994-01-24 Behandlung von Diabetes
PCT/US1993/012055 WO1995019785A1 (en) 1994-01-24 1994-01-24 Treatment for juvenile diabetes

Publications (1)

Publication Number Publication Date
DE69435212D1 true DE69435212D1 (de) 2009-07-16

Family

ID=22237287

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69435212T Expired - Fee Related DE69435212D1 (de) 1994-01-24 1994-01-24 Behandlung von Diabetes
DE69431212T Expired - Fee Related DE69431212T2 (de) 1994-01-24 1994-01-24 Behandlung von diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69431212T Expired - Fee Related DE69431212T2 (de) 1994-01-24 1994-01-24 Behandlung von diabetes

Country Status (8)

Country Link
EP (4) EP1842552A1 (de)
JP (1) JPH09511384A (de)
AT (1) ATE222503T1 (de)
AU (1) AU7628794A (de)
CA (1) CA2182034C (de)
DE (2) DE69435212D1 (de)
ES (1) ES2185663T3 (de)
WO (1) WO1995019785A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US5885956A (en) 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
AU2005201435A1 (en) * 1999-04-06 2005-04-28 Genentech, Inc. Use of ErbB receptor ligands in treating diabetes
IL145674A0 (en) * 1999-04-06 2002-06-30 Genentech Inc USE OF ERbB RECEPTOR LIGANDS IN TREATING DIABETES
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
EP1210102B1 (de) * 1999-08-19 2010-04-07 Applied Protein Sciences, LLC Tgf-alpha polypeptide, funktionelle fragmente und methoden zu deren verwendung
JP2004520345A (ja) * 2001-01-12 2004-07-08 ワラター・ファーマシューティカルズ・インク 糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続
EP1837031B1 (de) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
DE60329724D1 (de) * 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
CN1829528A (zh) * 2003-05-27 2006-09-06 瓦拉塔药品公司 包含胃泌素化合物的组合物及其在糖尿病中的应用
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8409961D0 (en) 1984-04-17 1984-05-31 Searle & Co Pharmaceutical compositions

Also Published As

Publication number Publication date
EP0752882A1 (de) 1997-01-15
EP1466618B1 (de) 2009-06-03
DE69431212T2 (de) 2003-04-10
AU7628794A (en) 1995-08-08
CA2182034A1 (en) 1995-07-27
JPH09511384A (ja) 1997-11-18
EP1132091A1 (de) 2001-09-12
DE69431212D1 (de) 2002-09-26
EP1466618A1 (de) 2004-10-13
EP1842552A1 (de) 2007-10-10
EP0752882A4 (de) 1999-09-01
CA2182034C (en) 2009-04-21
EP0752882B1 (de) 2002-08-21
ES2185663T3 (es) 2003-05-01
WO1995019785A1 (en) 1995-07-27
ATE222503T1 (de) 2002-09-15

Similar Documents

Publication Publication Date Title
DE69435212D1 (de) Behandlung von Diabetes
HUP9700368A2 (hu) II-típusú diabetes mellitus kezelése amilin agonistákkal
ES2083851T3 (es) Dispositivo para el tratamiento de cultivos de celulas.
EP0699686A3 (de) Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides
ATE316100T1 (de) Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE69534678D1 (de) Glucagonähnliche Peptide, Zusammensetzungen und Verfahren
DK0436469T3 (da) Præparat og fremgangsmåde til behandling af osteoporose i pattedyr
BG101392A (en) Method of treating diabetes mellitus using kgf
DE69926400D1 (de) Zusammensetzung enthaltend insulin-sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
DE69431046D1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
WO1996032087A3 (en) Transgenic fish in the treatment of diabetes
EP0675665A3 (de) Optische Zeitstufe und Betriebsverfahren.
DE69939937D1 (de) Translations-kontrollelemente für proteinexpression mit hoher ausbeute in den plastiden von höheren pflanzen und verfahren zu deren verwendung
NO900248L (no) Apparat til oppbevaring og avgivelse av langstrakte materialer.
HU9700598D0 (en) Process for profilacting and treating pancreatitis
AU2158688A (en) Use of bezafibrate for treating diabetes
DE59801891D1 (de) Verfahren zum thermischen behandeln von flüchtige, brennbare bestandteile enthaltendem material
DE69231036D1 (de) Verfahren zur behandlung von patienten mit chronischer lebererkrankung
AU4908385A (en) Priming and purging blood treatment apparatus
DE59509173D1 (de) Verwendung von BK-RiV-Präparaten als Arzneimittel zur Therapie von AIDS
MX9710291A (es) Inhibidores ligantes de proteinas de fijacion con factor de crecimiento del tipo de insulina y metodos de uso para los mismos.
NO871554L (no) Fremgangsmaate og apparat for paavisning av hydrogenholdigeeller hydrogenreaktive gasser.
ATA153088A (de) Neue 5-pyrimidincarboxamide, diese enthaltende pharmazeutische zusammensetzungen und verfahren zur behandlung von leukaemie mit diesen
ATA153188A (de) Neue 5-pyrimidincarboxamide, diese enthaltende pharmazeutische zusammensetzungen und verfahren zur behandlung von leukaemie mit diesen
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee